On January 23, our CSO, Pete Gagnon, had a presentation at Phacilitate Leaders World & World Stem Cell Summit 2020. He presented our Cornerstone process for industrial exosome purification. We hope that you found it informative and worthwhile.Those who were not able to attend can download the presentation here.
Developing an Anion Exchange Chromatography Assay for Determining Empty and Full Capsid Contents in AAV6.2
In this article, AstraZeneca developed a QC-friendly anion exchange chromatography (AEX) assay for the determination of empty and full capsid percentages. For this purpose they used AAV serotype 6.2 (AAV6.2). The reported assay requires several microliters of material with a minimum titer of 5 × 1011 vg/mL, and it can detect the presence of as low as 2.9% empty capsids in AAV6.2 samples. Additionally, the method is easy to deploy, can be automated, and has been successfully implemented to support testing of various in-process and release samples.
Oligo dT immobilization on CIMmic CDI-0.1 column
The increasing demand for mRNA as a therapeutic product requires larger production scales, and in turn more efficient extraction techniques.
One of the most convenient techniques for its extraction is the use of oligo deoxythymidine (dT) coupled to a solid support. In this study, amino-modified oligo dT (NH2-C6-dT18) was immobilized on CIMmic CDI monolith. The immobilisation was performed by following the manufacturer’s protocol and the functionality was confirmed by measuring the amount of bound and eluted mRNA.
Miniaturisation of trypsin immobilised enzymatic reactor for protein digestion
Miniaturised immobilised enzymatic reactors can be used for small scale digestion of proteins and there is always a need for such devices.
This application note compares the performance of a flow through miniaturised immobilised enzymatic reactor (μIMER ) with in-solution batch digestion of simple proteins and complex matrices. Pre-activated CIMmic™ monolithic columns bed volume were immobilised with trypsin from bovine pancreas. Pre-treated samples were injected into the column, and the eluate were subjected to different analysis for protein identification and post-translational modification determination.
The remarkable monolithic technology is opening up boundless new possibilites for accelerated gene therapy development. Do you want to learn more about it?